HanYu Pharma and KuCoin dey tokenize Innovative Drug Revenue Rights
For August 4, 2025, Chinese biotech company HanYu Pharmaceuticals don sign strategic cooperation memorandum with digital asset exchange KuCoin to launch Mainland China's first RWA tokenization pilot project. The plan na token the future revenue rights of GLP-1 peptide drug R&D, base for Hong Kong. HanYu Pharma provide deep pipeline and technical skill for GLP-1 therapeutics as underlying assets. KuCoin go deliver end-to-end RWA solutions like on-chain asset mapping, tokenization, trading matching, and revenue distribution. This partnership dey highlight growing trend for tokenization of real-world assets, wey wan connect innovative drug financing with blockchain liquidity. Traders suppose watch RWA sector opportunities plus KuCoin expansion for asset tokenization.
Bullish
Dis strategic partnership na dis one big milestone for di way real-world asset dey accepted. By tokenizing di future revenue rights of innovative drug research and development, HanYu Pharma and KuCoin open new channel for liquidity to help biotech finance. Before now, tokenization pilots like real estate or commodity RWA launches don attract big institutions and increase demand for related tokens. Short term, market players fit move capital go RWA projects and KuCoin tokenization services. Long term, if dis thing work well, e fit become example for more pharmaceutical and biotech RWA offerings, make di ecosystem stronger and improve access to alternative asset classes through blockchain.